The Connor Whole Health Integrative Oncology (CWHIO) Symptom Management Clinic combines physician visits covered by insurance with affordable group acupuncture sessions and massage therapy, bolstered by philanthropic funding for non-billable services. Between June 2023 and September 2024, the clinic provided nearly 2,000 treatments to 291 patients, delivering a hybrid model aimed at overcoming financial barriers often associated with integrative oncology.

Jacob Wolf, ND, LAc, the clinic’s Medical Director of Acupuncture, emphasized acupuncture’s role in alleviating symptom burden. “This program illustrates how integrative oncology can merge conventional treatments with evidence-based supportive therapies like acupuncture to enhance patient quality of life,” he stated. The program’s results show significant symptom reduction following single sessions, with pain scores dropping by an average of 2.08 points and nausea by 3.61 points on standardized scales.

Patient feedback mirrored clinical improvements, reflecting exceptional satisfaction: 87.1% strongly agreed they were satisfied with the services, and over 80% endorsed the program’s effectiveness for symptom management. Demand grew steadily, eventually peaking at 57 visits weekly, following the introduction of group acupuncture and personalized reiki therapies, underscoring robust patient interest in integrative options.

Embedded within the University Hospitals Seidman Cancer Center network, CWHIO aligns treatment plans with national integrative oncology guidelines from organizations such as the American Society of Clinical Oncology. This integration fosters multidisciplinary coordination while embedding holistic therapies into routine cancer care pathways.

Dr. Kristi Artz, Vice President of UH Connor Whole Health, noted the broader significance: “This study confirms strong patient demand for whole health approaches that integrate lifestyle and supportive therapies, while highlighting persistent systemic barriers restricting access.” The hybrid billing model—blending insurance coverage with accessible self-pay options—aims to surmount these barriers, enhancing equity in access to integrative care.

Most integrative oncology programs in the U.S. rely heavily on out-of-pocket payments, limiting reach and exacerbating disparities. By embedding these services within oncology workflows and prioritizing insurance-billed visits, the CWHIO model presents a novel solution, potentially facilitating broader adoption of integrative therapies nationwide.

This research marks a critical advance in supportive cancer care, promising to reshape symptom management by delivering comprehensive, patient-centered therapies through sustainable and accessible clinical pathways.

Subject of Research: Integrative Oncology Symptom Management
Article Title: Implementation and Patient-Reported Outcomes of an Insurance-Supported Integrative Oncology Symptom Management Program
News Publication Date: Not specified (publication forthcoming 2026)
Web References: https://ascopubs.org/doi/10.1200/OP-26-00274
References: Srivastava M, Rodgers-Melnick SN, Wolf J, Smith J, Rao S. JCO Oncol Pract. 2026;0(0):OP2600274. doi: 10.1200/OP-26-00274
Image Credits: University Hospitals
Keywords: Integrative Oncology, Acupuncture, Cancer Symptom Management, Insurance-Supported Healthcare, Patient-Reported Outcomes

Cancer, an ailment that not only affects the body but also impacts the essence of human experience, places its victims in an emotionally taxing realm. The qualitative nature of the research conducted by Owusu and colleagues provides a nuanced understanding of how cancer patients perceive their reality, particularly when receiving palliative care. Through in-depth interviews, the study captures the voices of these individuals, revealing stories of fear, isolation, and resilience as they navigate their illness.

One of the most striking findings of the research is the pronounced sense of isolation many cancer patients report during their treatment. Palliative care, often characterized by its focus on comfort and quality of life rather than curative measures, can inadvertently exacerbate feelings of solitude. Patients frequently describe a lack of understanding from their friends and family, who may be overwhelmed by the situation and unsure of how to provide support. This disconnect highlights the need for improved communication strategies within healthcare settings that foster community and support systems for patients.

Alongside isolation, anxiety emerges as a predominant theme in the study. For many patients, the unpredictability of their illness and the uncertainty surrounding their future creates a pervasive atmosphere of fear. This anxiety can be compounded by the practical challenges of managing healthcare appointments, treatment side effects, and family responsibilities. As documented in the research, the psychological burden of cancer extends far beyond physical symptoms, often leaving patients in a state of chronic worry and distress.

The study also delves into the impact of cultural factors on the experiences of cancer patients in Ghana. In many societies, cancer is shrouded in stigma and misconception, leading to further alienation for those affected. Many participants articulated their struggles with societal perceptions, where cancer is often equated with death, causing them to grapple with their identity and self-worth. Addressing these cultural dynamics is essential for developing a supportive environment that acknowledges the unique challenges faced by individuals in specific sociocultural contexts.

Moreover, the study emphasizes the critical role that healthcare professionals play in alleviating the psychosocial burden of palliative care patients. Participants expressed a strong desire for empathetic communication and active listening from healthcare providers. These findings underscore the importance of training for medical staff, not only in clinical skills but also in the psychosocial aspects of care. By fostering a more compassionate and understanding relationship between patients and providers, the potential for improved outcomes and patient satisfaction increases significantly.

Additionally, the family unit emerges as a significant contributor to the psychosocial landscape of cancer patients. The study notes that many participants relied heavily on family support systems, which often serve as their primary source of emotional strength. However, the stress of caregiving can also take a toll on family members, leading to a shared experience of suffering. This interconnectedness necessitates a comprehensive approach that includes family counseling and support services as integral components of palliative care.

In exploring the coping mechanisms adopted by cancer patients, the study identifies several strategies that individuals utilize to manage their emotional states. These range from engaging in spiritual practices to finding solace in art, music, or social interactions. Such self-directed methods underscore the resilience inherent in human nature, yet they also point to the need for structured support systems that can enhance these coping strategies and provide comprehensive care.

The findings of Owusu et al. extend beyond the mere identification of challenges; they pave the way for developing targeted interventions that address the specific needs of palliative care patients in Ghana. By tailoring programs that account for the emotional and psychological landscape explored in the research, healthcare facilities can improve the standard of care and better cater to the multifaceted needs of this vulnerable population.

As the landscape of cancer care evolves, the implications of this study resonate globally. It serves as a clarion call for healthcare systems across the world to address the often-overlooked psychosocial dimensions of palliative care. By enhancing our understanding of the patient experience and implementing supportive measures, we can work towards a future wherein quality of life is prioritized alongside physical well-being in cancer treatment.

The research conducted by Owusu et al. fosters dialogue around the significance of empathy, communication, and cultural awareness in palliative care. As healthcare providers continue to grapple with the complexities of cancer treatment, the lessons drawn from this study may hold the key to transforming the patient experience for the better. Ultimately, it is a reminder that beyond the clinical aspects of treatment lies the essence of humanity — a plea for compassion, understanding, and solidarity in the face of adversity.

This qualitative exploration underscores a critical point: cancer patients are not merely statistics; they are individuals with rich inner worlds, grappling with complex emotions. The stories captured in this research are a testament to the need for more than just medical interventions; they echo the call for comprehensive support that encompasses the psychosocial dimensions of cancer care. As we strive towards enhancing the quality of life for those affected by cancer, understanding their experiences and addressing their challenges remain paramount.

Through the lens of this groundbreaking research, we can envision a healthcare future where palliative care transcends traditional boundaries, fostering a more inclusive approach that recognizes the profound psychological landscapes of cancer patients. The call to action is clear — it is time to prioritize not only the physical alleviation of symptoms but also to embrace the emotional and social complexities that accompany the cancer experience.

In conclusion, Owusu et al.’s study is a significant stepping stone in reshaping how we perceive and respond to the needs of cancer patients in palliative care. By illuminating the psychosocial challenges they face, it empowers health professionals, policymakers, and the wider community to create an environment more conducive to healing. This research is a vital reminder that in the journey of cancer care, compassion must always accompany treatment — for it is in our shared humanity that we find the strength to support one another in the darkest of times.

Subject of Research: Psychosocial challenges of cancer patients receiving palliative care in Ghana

Article Title: A qualitative exploratory description of the psychosocial challenges of cancer patients receiving palliative care at a major teaching hospital in Ghana.

Article References:

Owusu, Y., Iddrisu, M., Quaidoo, T.G. et al. A qualitative exploratory description of the psychosocial challenges of cancer patients receiving palliative care at a major teaching hospital in Ghana. Discov Psychol 5, 112 (2025). https://doi.org/10.1007/s44202-025-00449-x

Image Credits: AI Generated

DOI: 10.1007/s44202-025-00449-x

Keywords: Cancer, palliative care, psychosocial challenges, Ghana, qualitative research.

The theme for this year’s ASCO assembly, “Driving Knowledge to Action. Building a Better Future,” underscores the critical nexus between cutting-edge research and patient-centered clinical application. City of Hope’s delegation is poised to contribute robust data sets and innovative research paradigms that spotlight precision oncology, novel therapeutic agents, and advanced management approaches for various malignancies including breast, pancreatic, colorectal, prostate, kidney, and hematologic cancers. Moreover, the emphasis on integrative and supportive care, such as palliative interventions, marks a progressive step towards holistic cancer treatment pathways that prioritize quality of life alongside survival metrics.

Central to City of Hope’s presentations are several key oral abstract and clinical symposium sessions that dissect tumor biology and therapeutic resistance in high-risk renal cell carcinoma. The IMmotion010 study, a randomized phase 3 trial exploring adjuvant atezolizumab versus placebo, will unveil comprehensive genomic characterizations of baseline and post-progression tumors. This analysis promises to elucidate mechanisms of immune evasion and tumor evolution, potentially guiding biomarker-driven treatment algorithms in kidney cancer. Leading this discourse is Dr. Sumanta Kumar Pal, a seasoned medical oncologist with extensive expertise in therapeutic research at City of Hope.

Complementing the genomic insights, City of Hope also emphasizes symptom science and palliative care, acknowledging the indispensable role these disciplines play in oncology. Dr. Tanyanika Phillips will chair a session focusing on the management of cancer-related symptoms and the integration of palliative care principles within standard oncology practice. This aligns with the growing recognition that addressing treatment side effects and symptom burden is fundamental to enhancing patient outcomes and curbing healthcare costs.

Dr. Heather Hampel’s involvement as chair and panelist in a session dedicated to hereditary cancer demonstrates City of Hope’s commitment to genetic risk stratification and precision prevention. By delving deeper into hereditary cancer risk and its clinical repercussions, the session will underscore advances in genetic counseling and germline testing that can personalize cancer surveillance and prophylactic strategies.

Rapid oral abstract sessions will highlight groundbreaking work in breast cancer therapy and hematologic malignancies. The investigation led by Dr. Hope S. Rugo into treatment rechallenge following trastuzumab-deruxtecan-related interstitial lung disease addresses a critical safety and efficacy question in metastatic breast cancer management. Understanding how to safely reintroduce this potent antibody-drug conjugate after pulmonary toxicity could expand therapeutic options for patients with resistant disease.

In leukemia research, Dr. Ibrahim T. Aldoss presents a post hoc analysis from the Phase 3 PhALLCON trial regarding minimal residual disease (MRD) negativity after induction therapy. MRD status serves as a highly sensitive biomarker predictive of relapse and survival, and optimizing treatment to achieve MRD negativity is a paramount goal in acute leukemia management. These findings can expedite the adoption of MRD-guided therapeutic decision-making.

Innovations in myeloma treatment will be critically discussed through City of Hope’s participation as a discussant in sessions exploring novel therapeutic avenues targeting plasma cell dyscrasias. Dr. Amrita Krishnan’s expertise enhances the dialogue surrounding emerging regimens and biomarker-driven interventions aimed at improving long-term disease control and patient quality of life in multiple myeloma.

Educational sessions curated by City of Hope further underscore emerging challenges in oncology. Dr. Hope S. Rugo’s presentation on managing endocrine toxicities serves to equip oncologists with best practices for mitigating adverse effects related to novel breast cancer therapies. This is pivotal as new agents with complex side effect profiles enter clinical use, requiring nuanced management strategies to maintain treatment adherence.

Pediatric oncology survivors’ morbidity reduction is addressed in a session led by Dr. Saro H. Armenian, who advocates for personalized intervention approaches. This focus highlights survivorship care as a critical extension of cancer therapy, addressing long-term consequences of childhood cancer treatment through tailored risk assessment and supportive care techniques.

Integrative oncology is also represented, with Dr. Krisstina Gowin presenting evidence-based guidelines for the management of cancer-associated pain, fatigue, and depression. By operationalizing ASCO’s supportive care guidelines into real-world practice, these sessions promote holistic, patient-centered care models that integrate conventional and complementary modalities.

Poster presentations extend the scope of City of Hope’s research portfolio, showcasing innovative clinical trial data across metastatic breast cancer, pancreatic ductal adenocarcinoma, colorectal cancer, and genitourinary malignancies. Notably, the NAPOLI 3 Phase 3 trial final overall survival analysis in metastatic pancreatic cancer, presented by Dr. Vincent Chung, offers fresh perspectives on treatment efficacy and long-term survival characteristics. Similarly, evaluations of novel immunotherapies and combinatorial regimens in kidney and prostate cancers provide important insights into optimizing sequencing and combination strategies.

Recognition of City of Hope faculty members such as Drs. Lorna Rodriguez-Rodriguez and Stacy W. Gray, who were inducted as fellows of the American Society of Clinical Oncology (FASCO), reflects the institution’s dedication to leadership in oncology research, education, and clinical excellence. This honor acknowledges their pivotal roles in fostering innovation and advancing standards of care to conquer cancer effectively.

City of Hope’s integrated research-to-practice model, underscored by its NCI-designated comprehensive cancer center, continues to influence oncology globally. The institution’s contributions at the 2025 ASCO Annual Meeting epitomize a mission-driven commitment to transforming complex cancer data into actionable clinical applications that improve patient survival and wellbeing. By converging basic science, translational research, and clinical expertise, City of Hope underscores the future of oncology—a future where knowledge unequivocally drives transformative cancer care.

As oncology confronts the challenges of heterogeneity, resistance mechanisms, and survivorship complexities, City of Hope’s broad research landscape—from molecular tumor characterization to supportive care innovation—foreshadows a new horizon in personalized and effective cancer management worldwide.

Subject of Research: Oncology research and clinical advancements across multiple cancer types, including renal cell carcinoma, breast cancer, pancreatic cancer, colorectal cancer, prostate cancer, kidney cancer, blood cancers, and supportive care modalities.

Article Title: City of Hope Unveils Pioneering Oncology Research at 2025 ASCO Annual Meeting

News Publication Date: Not specified in the provided content

Web References:

• https://meetings.asco.org/2025-asco-annual-meeting
• https://www.cityofhope.org/

References: Not explicitly provided in the content

Image Credits: Not provided

Keywords: Oncology, Cancer Research, Precision Medicine, Immunotherapy, Hematologic Malignancies, Breast Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Kidney Cancer, Clinical Trials, Supportive Care, Palliative Care